Rai Helped Launch an Age of Innovation in Leukemia
Kanti R. Rai, MD, has been a leader in the diagnosis and treatment of chronic lymphocytic leukemia for more than 40 years. He was honored in the Hematologic Malignancies category with a 2017 Giants of Cancer Care® award.
Dana-Farber Researcher Sees Biomarker Potential in ESR1 Mutations
Rinath M. Jeselsohn, MD, discusses the detection and clinical implications of ESR1 mutations.
Novel Frontline Regimens Are Emerging for Advanced Ovarian Cancer
Bradley J. Monk, MD, and other gynecologic oncology experts from across the United States discussed how new evidence has affected their approach to treating advanced ovarian cancer.
Growing Pains: OCM Results Need Close Look
Darcie Hurteau, MBA, and Alyssa Dahl, PhD, MPH, discuss the growing pains of the Oncology Care Model, a complicated payment program that is still establishing administrative processes.
ESR1 Mutations Take Center Stage in Metastatic ER-Positive Breast Cancer
Despite gaps in current knowledge, investigators are already working toward the development of novel treatment strategies to combat the effects of ESR1 mutations.
RET Inhibitor Tested in Multiple Tumor Types
Investigators are evaluating the potential of LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer, medullary thyroid cancer, and other tumors.
ASCO Adds New Combos for Metastatic Noncastrate Prostate Cancer
Use of androgen deprivation therapy in combination with docetaxel or abiraterone in newly diagnosed cases of metastatic noncastrate prostate cancer is recommended in recently updated ASCO guidelines.
Practices Struggle With Oncology Care Model Report Cards
The Oncology Care Model is a patient-centric program that the Centers for Medicare & Medicaid Services says will allow for “better care, smarter spending, and healthier people.”
Tumor-Treating Field Therapy Looks Beyond Brain Cancer
Tumor-treating field therapy, which uses low-intensity electrical fields to disrupt cancer cell division and promote cell death, has gained a frontline approval in glioblastoma. Several pivotal clinical trials have been launched to determine whether the technology can help patients with other solid tumors.
Reforms Would Add Value to the Randomized Trial
Maurie Markman, MD, discusses the increasing criticism of the phase III randomized trial in oncology.
Chemotherapy Followed by Endocrine Therapy Could Increase Cognitive Impairment in Breast Cancer, Irrespective of Menopausal Status
Racial Disparity Revealed in Prometastatic TME in Women With Residual Breast Cancer After Neoadjuvant Chemo
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.